Guggenheim raises Immunovant stock target to $46, maintains Buy
Guggenheim Securities updated their outlook on Immunovant (NASDAQ:IMVT) shares, raising the price target from $44.00 to $46.00 while maintaining a Buy rating on the stock. Currently trading at $23.23, ...
Interstitial Lung Disease Therapeutics Market Size in the 7MM is anticipated to increase by 2032 and according to DelveInsight
Press Release Distributed by ABNewswire.com To view the original version on ABNewswire visit: Interstitial Lung Disease ...
ZURA stock touches 52-week low at $1.75 amid market fluctuations
In a challenging economic environment, ZURA's stock has hit a 52-week low, dropping to $1.75. According to InvestingPro ...